Model‐Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70098 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Andrzej Bienczak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Chronic Urticaria, Drug Development, Models, Biological. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Model‐informed drug development (MIDD) has been increasingly applied to guide decision‐making, ameliorate efficiency, and enhance the likelihood of successful trials. The development of ligelizumab, a humanized anti‐IgE monoclonal antibody, in chronic spontaneous urticaria (CSU) illustrated how MIDD can be applied to support central aspects of drug development, such as dose selection and trial design, pediatric drug development and extrapolation, generation of evidence to support potential labeling, optimizing treatment outcomes, and enhancing patient access. In this manuscript, we provide an overview of the key modeling and simulation analyses that were part of the MIDD approach for the development of ligelizumab in CSU and how they were staggered around the availability of interim and final data from the Phase 2 and Phase 3 studies. Furthermore, we present details of the non‐linear mixed‐effects models characterizing the population pharmacokinetics and exposure‐response relationship of ligelizumab for efficacy in adolescent and adult patients with CSU.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novartis Pharma AG, Basel, Switzerland.
- Shanghai Novartis Trading Ltd, Shanghai, China.
- Novartis Pharmaceuticals Corp, East Hanover, New Jersey, USA.
ORCID-Profile: Andrzej Bienczak, Eva Hua, Yan Ji, Emil Scosyrev, Serge Smeets, Manmath Patekar, Marina Savelieva
Zitieren
APA
Bienczak, A., Gautier, A., Hua, E., Ji, Y., Scosyrev, E., Smeets, S., Severin, T., Drollmann, A., Patekar, M., & Savelieva, M. (2025). Model‐Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70098
Vancouver
Bienczak A, Gautier A, Hua E, Ji Y, Scosyrev E, Smeets S, et al. Model‐Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70098
BibTeX
@article{Bienczak2025,
author = {Bienczak, Andrzej and Gautier, Aurelie and Hua, Eva and Ji, Yan and Scosyrev, Emil and Smeets, Serge and Severin, Thomas and Drollmann, Anton and Patekar, Manmath and Savelieva, Marina},
title = {Model‐Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70098}
}
EUVIMED